Klein G L
Department of Pediatrics, University of Texas Medical Branch, Galveston.
Am J Clin Nutr. 1995 Mar;61(3):449-56. doi: 10.1093/ajcn/61.3.449.
It has been a dozen years since aluminum was first shown to contaminate parenteral nutrition solutions and to be a contributing factor in the pathogenesis of metabolic bone disease in parenteral nutrition patients as well as in uremic patients. However, there are no regulations in place to effectively reduce aluminum contamination of various parenterally administered nutrients, drugs, and biologic products. The purpose of this review is fourfold: 1) to summarize our knowledge of the adverse effects of aluminum on bone formation and mineralization in parenteral nutrition patients; 2) to discuss the possible role of aluminum in the osteopenic bone disease of preterm infants; 3) to show how lack of regulations covering aluminum content of parenteral solutions can lead to vulnerability of new groups of patients to aluminum toxicity, the example being given here is that of burn patients; and 4) to trace the development of efforts at regulating the aluminum contamination of large- and small-volume parenteral drug products and to point out what still needs to be done in this regard.
自首次发现铝会污染肠外营养溶液，并成为肠外营养患者以及尿毒症患者代谢性骨病发病机制的一个促成因素以来，已经过去了十二年。然而，目前尚无有效减少各种肠外给药的营养剂、药物和生物制品铝污染的相关规定。本综述的目的有四个：1）总结我们对铝对肠外营养患者骨形成和矿化的不良影响的认识；2）讨论铝在早产儿骨质疏松性骨病中可能发挥的作用；3）说明缺乏关于肠外溶液铝含量的规定如何导致新的患者群体易受铝中毒影响，此处所举例子为烧伤患者；4）追溯在规范大体积和小体积肠外药品铝污染方面所做努力的发展历程，并指出在这方面仍需开展的工作。
